Biomarkers of acute kidney disease. Potential application in practice

Cover Page

Cite item

Full Text

Abstract

Acute kidney injury (AKI) is a common clinical syndrome. Its variety of presentation explains the absence of “kidney troponin”. Many research projects of new biomarkers are ongoing now. The enormous number of biomarkers has been identified already. It makes difficult to choose the correct test and dictates the importance of the fastest and most accurate introduction of AKI biomarkers into clinical practice. The integration of appropriately selected biomarkers in routine clinical practice for high-risk patients of AKI is very important. Currently, serum creatinine (sCr) and urine output are used to define AKI in accordance with the definition of KDIGO (Kidney Disease: Improving Global Outcomes), which have a number of significant limitations for practitioners, including the inability to diagnose AKI before serum creatinine levels increase. Practitioners need systematic information about the latest AKI markers and possible situations, when and for which patient groups they can be used. This is the main goal of our review.

About the authors

Ekaterina S. Schelkanovtseva

Sechenov First Moscow State Medical University (Sechenov University); City Polyclinic №67

Email: mar-shhelkanovceva@yandex.ru
ординатор каф. факультетской терапии Moscow, Russia

Olga Iu. Mironova

Sechenov First Moscow State Medical University (Sechenov University)

канд. мед. наук, доц. каф. факультетской терапии Moscow, Russia

Viktor V. Fomin

Sechenov First Moscow State Medical University (Sechenov University)

чл.-кор. РАН, д-р мед. наук, проф., проректор по клинической работе и дополнительному профессиональному образованию, зав. каф. факультетской терапии Moscow, Russia

References

  1. Srisawat N, Kellum JA. The Role of Biomarkers in Acute Kidney Injury. Crit Care Clin 2020; 36 (1): 125-40. doi: 10.1016/j.ccc.2019.08.010
  2. Bihorac A, Chawla LS, Shaw AD, et al. Validation of Cell-Cycle Arrest Biomarkers for Acute Kidney Injury Using Clinical Adjudication. Am J Respir Crit Care Med 2014; 189 (8): 932-9. doi: 10.1164/rccm.201401-0077OC
  3. Ostermann M, Zarbock A, Goldstein S, et al. Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference. A Consensus Statement. JAMA Netw Open 2020; 3 (10): e2019209. doi: 10.1001/jamanetworkopen.2020.19209
  4. Guzzi LM, Bergler T, Binnall B, et al. Clinical use of TIMP-2/IGFBP7 biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel. Crit Care 2019; 23 (1): 225. doi: 10.1186/s13054-019-2504-8
  5. Kellum JA, Lameire N, Aspelin P, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Sppl 2012; 2 (1): 1-138. doi: 10.1038/kisup.2012.1
  6. Adler C, Heller T, Schregel F, et al. TIMP-2/IGFBP7 predicts acute kidney injury in out-of-hospital cardiac arrest survivors. Crit Care 2018; 22 (126): 1-8. doi: 10.1186/s13054-018-2042-9
  7. Noto A, Cortegi ani A, David A. NephroCheck: should we consider urine osmolality? Crit Care 2019;(1): 48. doi: 10.1186/s13054-019-2341-9
  8. Di Somma S, Magrini L, De Berardinis B, et al. Additive value of blood neutrophil gelatinaseassociated lipocalin to clinical judgement in acute kidney injury diagnosis and mortality prediction in patients hospitalized from the emergency department. Crit Care 2013; 17 (1): R29. doi: 10.1186/cc12510
  9. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 2012; 68 (9): 1243-55. doi: 10.1007/s00228-012-1259-9
  10. Hoste E, Bihorac A, Al-Khafaji A, et al. Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study. Intensive Care Med 2020; 46: 943-53. doi: 10.1007/s00134-019-05919-0
  11. Gaede L, Liebetrau C, Blumenstein J, et al. Plasma microRNA-21 for the early prediction of acute kidney injury in patients undergoing major cardiac surgery. Nephrol Dial Transplant 2016; 31 (5): 760-6. doi: 10.1093/ndt/gfw007
  12. Shah KS, Taub P, Patel M, et al. Proenkephalin predicts acute kidney injury in cardiac surgery patients. Clin Nephrol 2015; 83 (1): 29-35. doi: 10.5414/CN108387
  13. Cruz DN, Ricci Z, Ronco C. Clinical review: RIFLE and AKIN - time for reappraisal. Crit Care 2009;(3): 211. doi: 10.1186/cc7759
  14. Oh DJ. A long journey for acute kidney injury biomarkers. Ren Fail 2020; 42 (1): 154-65. doi: 10.1080/0886022X.2020.1721300
  15. Dasta JF, Kane-Gill SL, Durtschi AJ, et al. Costs and outcomes of acute kidney injury (AKI) following cardiac surgery. Nephrol Dial Transplant 2008; 23 (6): 1970-4. doi: 10.1093/ndt/gfm908
  16. Alshaikh HN, Katz NM, Gani F, et al. Financial impact of acute kidney injury after cardiac operations in the United States. Ann Thorac Surg 2018; 105 (2): 469-75. doi: 10.1016/j.athoracsur.2017.10.053
  17. Магзумова Г.Е., Гайпов А.Э., Толеп К.О., и др. Липокалин, ассоциированный с желатиназой нейтрофилов (NGAL) - ранний маркер острого повреждения почек. Клин. медицина Казахстана. 2014: 104-5 [Magzumova G.E., Gaipov A.E., Tolep K.O., et al. Lipokalin, assotsiirovannyi s zhelatinazoi neitrofilov (NGAL) - rannii marker ostrogo povrezhdeniia pochek. Klin. meditsina Ka-zakhstana. 2014: 104-5 (in Russian)].

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies